Epigenetically maintained SW13+ and SW13-subtypes have different oncogenic potential and convert with HDAC1 inhibition

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Davis, McKale R ^a   Daggett, Juliane J ^a   Pascual, Agnes S ^a   Lam, Jessica M ^a   Leyva, Kathryn J ^a   Cooper, Kimbal E ^a   Hull, Elizabeth E ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Adrenocortical carcinoma; BRM; Chromatin remodeling; Epigenetic regulation; HDAC inhibitors; Histone modification; SWI SNF

Indexed keywords

BRM PROTEIN; HISTONE DEACETYLASE 1; MATRIX METALLOPROTEINASE; ONCOPROTEIN; UNCLASSIFIED DRUG; VIM PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; SMARCA2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADRENAL CORTEX CARCINOMA; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL LINE; CANCER MORPHOLOGY; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SW13+ CANCER CELL LINE; SW13- CANCER CELL LINE; WESTERN BLOTTING; ACETYLATION; ADRENAL CORTEX TUMOR; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; METASTASIS; PHENOTYPE; PROCEDURES; TUMOR CELL LINE;

ACETYLATION; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; NEOPLASM METASTASIS; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 85007467147     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2353-7     Document Type: Article

References (55)

1. Sarria AJ, Lieber JG, Nordeen SK, Evans RM. The presence or absence of a vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. J Cell Sci. 1994;107(6):1593-607.
2. Dunaief JL, Strober BE, Guha S, Khavari PA, �lin K, Luban J, Begemann M, Crabtree GR, GoffSP. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell. 1994;79(1):119-30.
3. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, GoffSP, Yaniv M et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 1996;15(19):5370-82.
4. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28(14):1653-68.
5. Medina PP, Sanchez-Cespedes M. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics. 2008;3(2):64-8.
6. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat. 2008;29(5):617-22.
7. Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatinremodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosom Cancer. 2004;41(2):170-7.
8. Kahali B, Yu J, Marquez SB, Thompson KW, Liang SY, Lu L, Reisman D. The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors. Oncotarget. 2014;5(10):3316-32.
9. Kim KH, Roberts CW. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet. 2014;207(9):365-72.
10. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592-601.
11. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8(1):e55119.
12. Yamamichi-Nishina M, Ito T, Mizutani T, Yamamichi N, Watanabe H, Iba H. SW13 cells can transition between two distinct subtypes by switching expression of BRG1 andBrm genes at the post-transcriptional level. J Biol Chem. 2003;278(9):7422-30.
13. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007;26(49):7058-66.
14. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124(1):30-9.
15. Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y, Liu P. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol (London, England). 2013;9(2):255-69.
16. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anti-Cancer Drugs. 2014; 25(2):140-9.
17. George SJ, Johnson JL. In Situ Zymography. In: Matrix Metalloproteinase Protocols. Volume 622. 2009. p. 271-7.
18. Forthofer RN, Lee ES, Hernandez M. Biostatistics: a guide to design, analysis, and discovery. 2nd ed. Amsterdam: Elsevier Academic Press; 2007.
19. Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, Kimura S, Ito T, Yahagi N, Ichinose M, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005;24(35):5471-81.
20. Santilman V, Baran J, Anand-Apte B, Evans RM, Parat MO. Caveolin-1 polarization in transmigrating endothelial cells requires binding to intermediate filaments. Angiogenesis. 2007;10(4):297-305.
21. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-48.
22. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget M-C, Kalita A, Liu J, Lu A-H, Zhou NZ, Robert M-F et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7(4):759-68.
23. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008; 409(2):581-9.
24. Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M et al. FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002; 62(17):4916-21.
25. Borutinskaite VV, Magnusson K-E, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep. 2012;39(12):10179-86.
26. Marks BD, Fakhoury SA, Frazee WJ, Eliason HC, Riddle SM. A substrateindependent TR-FRET histone deacetylase inhibitor assay. J Biomol Screen. 2011;16(10):1247-53.
27. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci. 1998;95(7):3356-61.
28. Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013;9(5):319-25.
29. Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, Rusche JR, Wood MA. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci. 2013; 110(7):2647-52.
30. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem. 2008;51(15):4370-3.
31. Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2a). EMBO J. 1998;17(23):6979-91.
32. Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, Yeudall WA. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther. 2008;7(9):2894-903.
33. Longworth MS, Laimins LA. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene. 2006;25(32):4495-500.
34. Soriano FX, Chawla S, Skehel P, Hardingham GE. SMRT-mediated coshuttling enables export of class IIa HDACs independent of their CaM kinase phosphorylation sites. J Neurochem. 2013;124(1):26-35.
35. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang X-J, Dent SR et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27(2):197-213.
36. Yin F, Lan R, Zhang X, Zhu L, Chen F, Xu Z, Liu Y, Ye T, Sun H, Lu F et al. LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16. Mol Cell Biol. 2014;34(2):158-79.
37. Shia W-J, Li B, Workman JL. SAS-mediated acetylation of histone H4 Lys 16 is required for H2A.Z incorporation at subtelomeric regions in saccharomyces cerevisiae. Genes Dev. 2006;20(18):2507-12.
38. Shogren-Knaak M, Ishii H, Sun J-M, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006;311(5762):844-7.
39. Bell O, Schwaiger M, Oakeley EJ, Lienert F, Beisel C, Stadler MB, Schubeler D. Accessibility of the Drosophila genome discriminates PcG repression, H4K16 acetylation and replication timing. Nat Struct Mol Biol. 2010;17(7):894-900.
40. Horikoshi N, Kumar P, Sharma G, Chen M, Hunt C, Westover K, Chowdhury S, Pandita T. Genome-wide distribution of histone H4 Lysine 16 acetylation sites and their relationship to gene expression. Genome Integr. 2013;4(1):3.
41. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;30(31):3391-403.
42. Huang P-H, Chen C-H, Chou C-C, Sargeant AM, Kulp SK, Teng C-M, Byrd JC, Chen C-S. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol. 2011;79(1):197-206.
43. Whitehouse I, Flaus A, Cairns BR, White MF, Workman JL, Owen-Hughes T. Nucleosome mobilization catalysed by the yeast SWI/SNF complex. Nature. 1999;400(6746):784-7.
44. Zofall M, Persinger J, Kassabov SR, Bartholomew B. Chromatin remodeling by ISW2 and SWI/SNF requires DNA translocation inside the nucleosome. Nat Struct Mol Biol. 2006;13(4):339-46.
45. Hauk G, McKnight JN, Nodelman IM, Bowman GD. The chromodomains of the Chd1 chromatin remodeler regulate DNA access to the ATPase motor. Mol Cell. 2010;39(5):711-23.
46. Liu CL, Kaplan T, Kim M, Buratowski S, Schreiber SL, Friedman N, Rando OJ. Single-nucleosome mapping of histone modifications in S. cerevisiae. PLoS Biol. 2005;3(10):e328.
47. Yen K, Vinayachandran V, Batta K, Koerber RT, Pugh BF. Genome-wide nucleosome specificity and directionality of chromatin remodelers. Cell. 2012;149(7):1461-73.
48. Ho L, Miller EL, Ronan JL, Ho WQ, Jothi R, Crabtree GR. esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. Nat Cell Biol. 2011;13(8):903-13.
49. Watanabe H, Mizutani T, Haraguchi T, Yamamichi N, Minoguchi S, Yamamichi-Nishina M, Mori N, Kameda T, Sugiyama T, Iba H. SWI//SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene. 2005;25(3):470-9.
50. Battaglioli E, Andr�s ME, Rose DW, Chenoweth JG, Rosenfeld MG, Anderson ME, Mandel G. REST repression of neuronal genes requires components of the hSWI�SNF complex. J Biol Chem. 2002;277(43):41038-45.
51. John S, Sabo PJ, Johnson TA, Sung M-H, Biddie SC, Lightman SL, Voss TC, Davis SR, Meltzer PS, Stamatoyannopoulos JA et al. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell. 2008;29(5):611-24.
52. Burd CJ, Ward JM, Crusselle-Davis VJ, Kissling GE, Phadke D, Shah RR, Archer TK. Analysis of chromatin dynamics during glucocorticoid receptor activation. Mol Cell Biol. 2012;32(10):1805-17.
53. Fryer CJ, Archer TK. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature. 1998;393(6680):88-91.
54. Hassan AH, Prochasson P, Neely KE, Galasinski SC, Chandy M, Carrozza MJ, Workman JL. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell. 2002; 111(3):369-79.
55. Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005;65(9):3542-7.